Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, lif...
Q1 2026
May 12, 2026
FY 2025
Mar 26, 2026
Q4 2025
Q3 2025
Nov 14, 2025
Q2 2025
Aug 14, 2025